Recital 13, Regulation (EU) 2022/860

In forcesince 1 Jun 2022

The Commission asked the Authority for technical assistance on two scientific studies, a systematic review and meta-analysis of the safety of red yeast rice supplementation [Fogacci F, Banach M, Mikhailidis DP et al. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research 143 (2019) 1–16.], and a review and expert opinion on the role of red yeast rice supplementation in plasma cholesterol control [Banach M, Bruckert E, Descamps OS et al. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. Atheroscler Suppl. 2019 Aug 17.], that were submitted to the Commission by an interested party following adoption of the scientific opinion by the Authority. The Authority noted that irrespective of the results of any intervention study or meta-analysis on the safety of red yeast rice supplementation, reports of side effects associated with the consumption of red yeast rice in humans exist and monacolin K in lactone form is identical to lovastatin for which adverse effects are well documented, and therefore those submitted studies would have to be considered together with the whole body of evidence to draw an overall conclusion. The Authority explained that the existence of reports of adverse effects cannot be neglected or invalidated by results of trials that were relatively small in size and not designed to detect these effects, and that studies, such as the review and expert opinion study submitted, providing comparative risk-benefit ratio of products containing red yeast rice were not relevant to the evaluation of the safety of substances intentionally added to food.